Kuehn Law is investigating Regenxbio, Inc. for allegedly providing false or misleading information about the safety and efficacy of its gene therapy trial for Hurler Syndrome. The lawsuit claims Regenxbio made overly positive statements about the trial's success based on ongoing Phase I/II study data. Shareholders who bought Regenxbio stock before February 9, 2022, are encouraged to contact the law firm to potentially enforce their rights. This case highlights concerns about transparency and accuracy in biotech trial reporting, which can impact investor decisions and market trust.
Arrowhead Pharmaceuticals saw its stock rise over 21% after positive late-stage trial results for its drug plozasiran, which significantly lowered triglyceride levels in patients with severe hypertriglyceridemia. Chardan Capital raised the price targ...
UBS has maintained a Market Perform rating on Comcast stock ahead of its Q2 earnings report, reflecting caution due to expected declines. Comcast is projected to report a 22.4% drop in earnings per share to $0.97 and a 3.75% revenue decrease to about...
City Holding Company reported strong Q2 2026 results with earnings per share (EPS) of $2.35, beating analyst estimates by nearly 6%. Quarterly revenue reached $81.52 million, up 4.3% year-over-year and slightly above expectations. This marks continue...
BankUnited reported Q2 2026 earnings per share of $0.97 and revenues of $284.57 million, both below analyst expectations. Despite the earnings miss, the bank achieved record growth in non-interest-bearing demand deposits, which reached 34.4% of total...
Rogers Communication reported better-than-expected Q2 2026 results, with earnings per share of $0.83 beating estimates of $0.80 and revenue reaching $3.96 billion, surpassing forecasts. The company showed improved financial discipline by increasing f...
